Souhaitez-vous accéder aux communiqués récents ?

Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine...

~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in...

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American:...

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial, Securing Alignment with FDA and EMA

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Gotistobart zeigte einen klinisch relevanten Gesamtüberlebensvorteil im Vergleich zur Standard-Chemotherapie und ein kontrollierbares Sicherheitsprofil

Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard chemotherapy and a manageable safety profile in sqNSCLC

CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted...